Quality Controls for IVT-RNA Vaccine and Drug Development

Infectious diseases are on the rise worldwide, with the importance of fast, effective vaccine production growing in importance to counter such threats.

During the Covid-19 pandemic, in vitro transcribed (IVT) RNA vaccines proved to be a highly effective tool in disease control. Fast, agile production enabled mRNA vaccines to save countless lives. And robust, reliable, and rapid quality control methods are a vital component of production.

This whitepaper introduces pandemics and vaccines and explains what sets IVT-RNA vaccines apart from conventional alternatives. Crucially, the document introduces the automated electrophoresis systems that played a pivotal role in aiding the development of Covid-19 vaccines.

From Agilent’s Bioanalyzer to the Fragment Analyzer and TapeStation system, this whitepaper explores the technology behind quality control for mRNA vaccine production, and the role that IVT-RNA vaccines look set to play in future.

Enter your details here to receive your free whitepaper.

By clicking the “Submit” button above, you accept the terms and conditions and acknowledge that your data will be used as described in the Agilent Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.